Plain-English translation of NCT06625073 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
Heart transplant recipients often develop kidney disease and other heart-related complications over time. This trial is testing whether , a medication that works by helping the kidneys filter glucose, can protect kidney function and reduce these long-term problems. Half of the participants will receive the medication, and half will receive a placebo (an inactive pill that looks the same).
Large studies have shown that this medication can protect kidney and heart health in other patient groups, but it has never been properly tested in heart transplant recipients—even though they may benefit even more than others. This trial aims to fill that gap and see if this treatment is safe and effective specifically for transplant patients.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to take either 10 mg or a matching placebo pill once daily for 12 months. You'll have baseline testing done before starting, and the research team will monitor your kidney function, heart health, and overall well-being throughout the study. Your participation will help doctors understand whether this medication can improve long-term health outcomes for heart transplant recipients.
AI-generated summary from trial data · Aug 9, 2026 · Not medical advice
United States